Menu
Search
|

Menu

Close
X

MorphoSys AG MOR.OQ (NASDAQ Stock Exchange Global Select Market)

27.95 USD
+0.11 (+0.40%)
As of Jul 19
Previous Close 27.84
Open 28.23
Volume 27,483
3m Avg Volume 14,488
Today’s High 28.27
Today’s Low 27.95
52 Week High 35.89
52 Week Low 21.75
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
--
7.97
Price to Book (MRQ)
vs sector
--
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
--
17.60
LT Debt to Equity (MRQ)
vs sector
--
12.58
Return on Investment (TTM)
vs sector
--
12.69
Return on Equity (TTM)
vs sector
--
17.17

EXECUTIVE LEADERSHIP

Marc Cluzel
Chairman of the Supervisory Board, Since 2018
Salary: €52,160.00
Bonus: --
Simon Moroney
Member of the Management Board, Chief Executive Officer, Since 1998
Salary: €500,876.00
Bonus: €1,037,240.00
Frank Morich
Independent Vice Chairman of the Supervisory Board, Since 2015
Salary: €57,240.00
Bonus: --
Jens Holstein
Chief Financial Officer, Member of the Management Board, Since 2011
Salary: €372,652.00
Bonus: €733,785.00
David Trexler
President - MorphoSys US Inc, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Semmelweisstr. 7
PLANEGG     82152

Phone: +4989.899270

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

SPONSORED STORIES